+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Association Between Statin Use After Diagnosis of Esophageal Cancer and Survival: A Population-Based Cohort Study



Association Between Statin Use After Diagnosis of Esophageal Cancer and Survival: A Population-Based Cohort Study



Gastroenterology 150(4): 854-65.E1; Quiz E16-7



Statins (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors), commonly prescribed in the primary and secondary prevention of cardiovascular disease, promote apoptosis and limit proliferation of esophageal cancer cell lines. We investigated whether statin use after a diagnosis of esophageal cancer is associated with reduced esophageal cancer-specific and all-cause mortality. We identified a cohort of 4445 men and women in the United Kingdom diagnosed with esophageal cancer from January 2000 through November 2009 using the General Practice Research Database. The National Cancer Registry and Office of National Statistics datasets established the histologic subtype and cancer-specific mortality, respectively. Cox proportional hazard regression analysis with time-dependent exposures estimated the association between statin use after diagnosis and esophageal cancer-specific and all-cause mortality. The median survival time of the entire cohort was 9.2 months (interquartile range [IQR], 3.7-23.2 mo). Among subjects who used statins after a diagnosis of esophageal cancer, the median survival time was 14.9 months (IQR, 7.1-52.3 mo) compared with 8.1 months for nonusers (IQR, 3.3-20 mo). In the entire cohort, statin use after diagnosis was associated with a decreased risk of esophageal cancer-specific mortality (adjusted hazard ratio [HR], 0.62; 95% confidence interval [CI], 0.44-0.86) and all-cause mortality (HR, 0.67; 95% CI, 0.58-0.77). In patients with esophageal adenocarcinoma, statin use after diagnosis was associated with a decreased risk of esophageal cancer-specific mortality (HR, 0.61; 95% CI 0.38-0.96) and all-cause mortality (HR, 0.63; 95% 0.43-0.92). This effect was not observed in patients with esophageal squamous cell carcinoma. There was no evidence for effect modification of these associations with statin use before the cancer diagnosis. In a large population-based cohort, statin use after a diagnosis of esophageal adenocarcinoma, but not esophageal squamous cell carcinoma, was associated with reduced esophageal cancer-specific and all-cause mortality.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 057247567

Download citation: RISBibTeXText

PMID: 26775632

DOI: 10.1053/j.gastro.2015.12.039


Related references

Statin use after esophageal cancer diagnosis and survival: A population based cohort study. Cancer Epidemiology 48: 124-130, 2017

Statin use after diagnosis of breast cancer and survival: a population-based cohort study. Epidemiology 26(1): 68-78, 2015

Statin use after colorectal cancer diagnosis and survival: a population-based cohort study. Journal of Clinical Oncology 32(28): 3177-3183, 2014

Statin use after diagnosis is associated with an increased survival in esophageal cancer patients: a Belgian population-based study. Cancer Causes and Control 2019, 2019

The association between statin use and the diagnosis of prostate cancer in a population based cohort. Journal of Urology 184(2): 494-499, 2010

Statin use and survival from lung cancer: a population-based cohort study. Cancer Epidemiology, Biomarkers and Prevention 24(5): 833-841, 2016

Statin use, Candidate Mevalonate Pathway Biomarkers, and Colon Cancer Survival in a Population-Based Cohort Study. Gastroenterology 152(5): S1023-S1024, 2017

Statin use and survival in colorectal cancer: Results from a population-based cohort study and an updated systematic review and meta-analysis. Cancer Epidemiology 45: 71-81, 2016

Psychiatric morbidity and survival after surgery for esophageal cancer: a population-based cohort study. Journal of Clinical Oncology 33(5): 448-454, 2015

The National Cohort of Esophageal Cancer-Prospective Cohort Study of Esophageal Cancer and Precancerous Lesions based on High-Risk Population in China (NCEC-HRP): study protocol. Bmj Open 9(4): E027360, 2019

Effects of socioeconomic status on esophageal adenocarcinoma stage at diagnosis, receipt of treatment, and survival: A population-based cohort study. Plos One 12(10): E0186350, 2017

Association between education level and prognosis after esophageal cancer surgery: a Swedish population-based cohort study. Plos One 10(3): E0121928, 2016

Digoxin use after diagnosis of colorectal cancer and survival: a population-based cohort study. Cancer Epidemiology, Biomarkers and Prevention 24(11): 1804-1807, 2016

Digoxin use after diagnosis of breast cancer and survival: a population-based cohort study. Breast Cancer Research and Treatment 151(3): 661-669, 2016

Digoxin use after diagnosis of prostate cancer and survival: a population-based cohort study. Pharmacoepidemiology and Drug Safety 25(9): 1099-1103, 2017